NASDAQ / LIVE COMPANY INTELLIGENCE

Voyager Therapeutics, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERVYGR
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / VYGR COVERAGE

What’s moving Voyager Therapeutics, Inc. now

Current reporting with the operating signal separated from the noise.

01
Voyager Therapeutics, Inc.: Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer ...

Voyager Therapeutics, Inc.: Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer ...

The story matters when it changes Voyager Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
Voyager Therapeutics, Inc. (VYGR) Discusses Tracer AAV Capsid Platform for Enhanced CNS Gene Therapy Delivery Transcript

Voyager Therapeutics, Inc. (VYGR) Discusses Tracer AAV Capsid Platform for Enhanced CNS Gene Therapy Delivery Transcript

The story matters when it changes Voyager Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: official volume, pricing, inventory and segment margin.
03
Voyager Therapeutics, Inc. (VYGR) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript

Voyager Therapeutics, Inc. (VYGR) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript

The story matters when it changes Voyager Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
04
Voyager Therapeutics, Inc. (VYGR): A Cheap Biotech Stock to Invest In Now

Voyager Therapeutics, Inc. (VYGR): A Cheap Biotech Stock to Invest In Now

Investors are testing whether Voyager Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
05
Voyager Therapeutics, Inc. (VYGR): Is This Gene Therapy Stock a Good Buy Right Now?

Voyager Therapeutics, Inc. (VYGR): Is This Gene Therapy Stock a Good Buy Right Now?

Investors are testing whether Voyager Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
PRIMARY DOCUMENTS / SEC EDGAR

Latest VYGR filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-07 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-10 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-03-09 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-07-13 · Period 2026-07-13SEC ↗8-KMaterial company eventFiled 2026-06-10 · Period 2026-06-09SEC ↗8-KMaterial company eventFiled 2026-06-01 · Period 2026-06-01SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-28 · Period 2026-06-09SEC ↗SCHEDULE 13G/AOfficial SEC filingFiled 2026-07-31SEC ↗
EARNINGS / QUARTERLY TRACKER

Voyager Therapeutics, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.